Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70 percent of the company’s workforce, only weeks after Bristol Myers Squibb abandoned its clinical collaboration program with Nektar on bladder cancer and renal cell carcinoma. 

Published April 7, 2022 By Vanessa Doctor, RN BioSpace Shares in Acadia Pharmaceuticals rose 5.71% to $27.22 per share at the close of NASDAQ Wednesday on positive late-stage data from the study of an investigational treatment for Rett syndrome. The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy […]

Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.

Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.

As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.

Seattle-based Icosavax’s stock plunged more than 60 percent on March 25 after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial. 

Pharmaceutical giant Roche and subsidiary Genentech announced a new Phase III clinical trial for gantenerumab, a monoclonal anti-amyloid antibody that is designed to treat Alzheimer’s disease.

Takeda and Code Biotherapeutics announced a collaboration agreement to leverage the latter’s proprietary targeted 3DNA non-viral genetic medicine delivery platform for the design and development of gene therapies for rare diseases.

The U.S. Food and Drug Administration sent Denali Therapeutics a formal clinical hold letter regarding the investigational new drug (IND) application for the company’s Alzheimer’s drug candidate DNL919.

Ventus Therapeutics, which is developing therapies aimed at diseases of the innate immune system, closed a $140 million Series C financing round that will be used to drive three lead programs into the clinic during 2022.